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Abstract
Background: Increasing evidence suggests that microRNAs (miRNAs) play critical roles in malignant transformation,
tumor progression and metastasis. Aberrant miR-655-3p expression has been associated with several cancers.
However, the role and underlying mechanism of miR-655-3p in the development of hepatocellular carcinoma (HCC)
remains unclear.
Methods: MiR-655-3p expression was detected by quantitative RT-PCR (qRT-PCR) in human HCC tissues and cell
lines. Cell proliferation was investigated using MTT and colony formation assays, and cell migration and invasion
abilities were evaluated by transwell assay. ADAM10 protein expression was detected by immunohistochemical
assay. The target gene and downstream of miR-655-3p were determined by qRT-PCR, western blot and dual-luciferase
reporter assays.
Results: miR-655-3p was significantly down-regulated in HCC tissues and HCC cell lines. Low miR-655-3p expression
was negatively related to tumor size, portal vein tumor thrombosis (PVTT) status, TNM stage and metastasis status. In
addition, miR-655-3p overexpression and depletion decreased and increased HCC cell proliferation, migration and
invasion, respectively. Moreover, ADAM10 was identified as a direct target of miR-655-3p, and miR-655-3p
down-regulated E-cadherin protein level and inhibits β-catenin pathway by mediating ADAM10.
Conclusions: MiR-655-3p might functions as a tumor suppressor by directly targeting ADAM10 and indirectly
regulating β-catenin pathway in the development of progression of HCC. It may be a novel therapeutic candidate
target to in HCC treatment.
Keywords: miR-655-3p, Hepatocellular carcinoma, ADAM10, β-catenin pathway, Proliferation, Migration and invasion
Background
Hepatocellular carcinoma (HCC), accounting for 85-
90 % of primary liver cancers, is the fifth most frequent
malignancy and the second leading cause of cancer-
related death in developing countries [1, 2]. There are
many risk factors related to HCC, especially hepatitis B
and C viruses and liver cirrhosis [3]. Despite increasing
significant advances in surgical techniques and diagnos-
tic methods in recent years, the long-time survival is still
unsatisfactory mainly due to the high rate of recurrence,
metastasis, and emergence of new primary tumors in
post operation [4, 5]. Unfortunately, the mechanisms of
high rate of recurrence and metastasis in HCC remain
unclear. Therefore, it is urgent to identify the new mo-
lecular biomarkers in predicting the aggressive biology of
HCC and guiding effective treatment for HCC patients.
MicroRNAs (miRNAs) are 18-24 nucleotides, small,
single-stranded, non-coding RNAs that regulate gene
expression by directly degrading mRNA or suppressing
post-transcriptional protein translation usually by bind-
ing to the 3’ untranslated region (3’ -UTR) of the re-
spective target mRNAs [6]. It has been confirmed that
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ample miRNAs can function as tumor suppressors or
oncogenes to play important roles in the initiation, pro-
motion and progression of various cancers [7], and aber-
rant miRNAs expression might be of potential use as a
diagnostic and prognostic biomarker for human cancer
including HCC. For example, miR-20, miR-182, miR-494,
and miR-125b have been proved to regulate tumor cell
growth, migration and invasion in HCC [8–11].
There are several miRNAs encoded in 14q32 locus,
including miR-655-3p, miR-127-5p, miR-369-3p, miR-
544a. MiRNAs on this locus have been reported associ-
ated with a metastatic phenotype in clinical cancer
samples [12], and ectopic expression of 14q32-encoded
microRNAs can reduce cell-autonomous metastatic
properties in vitro and inhibit metastasis development
in vivo [13]. MiR-655-3p expression is reduced in several
cancers and overexpression of miR-655 act as a tumor
suppressor by targeting pituitary tumor-transforming
gene-1(PTTG1) in esophageal squamous cell carcinoma
metastasis [14]. Previous study has demonstrated that
miR-655inhibits epithelial mesenchymal transition (EMT)
suppressive miRNA by targeting regulate ZEB1 and
TGFBR2 inducing inactivation of the TGF-β signaling
pathway [15]. In addition, miR-134/487b/655 cluster is
also reported to regulate TGF-β induced EMT and gefi-
tinib resistance by targeting MAGI2 in lung adenocar-
cinoma cells [16]. However, the expression level of
miR-655-3p and its roles in the development of HCC
have not yet been reported.
In the current study, we investigated the biological
function and molecular mechanism of miR-655-3p in
HCC. MiR-655-3p was significantly decreased in HCC
clinical specimens and cell lines. Overexpression of
miR-655-3p suppressed cell proliferation, migration
and invasion of HCC in vitro. Further study showed
that miR-655-3p could down-regulate E-cadherin and
inhibit β-catenin pathway by targeting A Disintegrin
and Metalloprotease Domain 10(ADAM10). Our find-
ings elucidated the detailed roles of miR-655-3p in
HCC and further contribute to offering the effective
therapeutic targets for the treatment of HCC.
Methods
Patients and specimens
Primary tumor tissues and their corresponding adjacent
non-tumorous liver specimens were obtained from 84
patients who were diagnosed with HCC during hepatic
resection in the First Affiliated Hospital of China Med-
ical University between July 2013 and July 2014. None
had received preoperative radiotherapy or chemotherapy
before surgery. Fresh specimens were snap-frozen and
stored in liquid nitrogen tanks immediately after resec-
tion. The clinical and pathological parameters are shown
in Table 1. This study protocol was approved by the
Institutional Ethics Committee of China Medical Univer-
sity, and human tumor tissues for this research were ob-
tained with informed consent.
HCC cell lines and cell cultures
Seven HCC cell lines, HepG2, SK-hep1, HCCLM3,
Huh7, MHCC-97H, MHCC-97 L, BEL-7402, and one
normal liver cell line, LO2, were used in this study. The
Huh7, BEL-7402, SK-hep1, HCCLM3 and LO2 human
cell lines were obtained from the Institute of Biochem-
istry and Cell Biology at the Chinese Academy of
Table 1 miR-655-3p expression and clinicopathological features
in hepatocellular carcinoma patients
Characteristics miR-655-3p expression p-value
Cases Low middle/High
Age (years)
≥ 53 43 27(62.8 %) 16(37.2 %) 0.69
< 53 41 24(58.5 %) 17(41.5 %)
Gender
Male 71 45(63.4 %) 26(36.6 %) 0.242
Female 13 6(46.2 %) 7(53.8 %)
HBsAg status
Positive 62 36(58.1 %) 26(41.9 %) 0.404
Negative 22 15(68.2 %) 7(31.8 %)
AFP (ng/ml)
≥ 20 48 30(62.5 %) 18(37.5 %) 0.699
< 20 36 21(58.3 %) 15(41.7 %)
Liver cirrhosis
Yes 63 38(60.3 %) 25(49.7 %) 0.897
No 21 13(61.9 %) 8(39.1 %)
Tumour size (cm)
< 5 44 22(50 %) 22(50 %) 0.035*
≥ 5 40 29(72.5 %) 11(27.5 %)
PVTT
Yes 9 9(100.0 %) 0(0.0 %) 0.028*
No 75 42(56 %) 33(44 %)
TNM Classification
I + II 50 24(48 %) 26(52 %) 0.004**
III + IV 34 27(79.4 %) 7(20.6 %)
Tumour differentiation
Well 37 21(56.8 %) 16(43.2 %) 0.721
Moderate 34 21(61.8 %) 13(48.2 %)
Poor 13 9(69.2 %) 4(30.8 %)
Metastasis
Yes 33 27(81.8 %) 6(18.2 %) 0.001**
No 51 24(47.1 %) 27(52.9 %)
Abbreviations: AFP alpha-fetoprotein, HBsAg hepatitis B surface antigen, TNM
tumor-node-metastasis, PVTT portal vein tumor thrombosis. * p<0.05; ** p<0.01
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Sciences (Shanghai, China). The HepG2, MHCC97H
and MHCC97L cells were obtained from Chinese Acad-
emy of Medical Sciences (Beijing, China). HCCLM3,
Huh7, HepG2, MHCC97H, MHCC97L were cultured
in DMEM medium. BEL-7402, SK-Hep1, LO2 were cul-
tured in RPMI 1640 medium. All the medium was
added with 10 % fetal bovine serum (FBS) and 100
units/ml of penicillin and streptomycin (Hyclone,
USA). All cells were grown in a humidified incubator
with 5 % CO2 at 37 °C.
RNA preparation and quantitative real-time PCR
Total RNA from HCC tissue samples and adjacent non-
tumorous tissue samples was extracted using Trizol Re-
agent (Invitrogen, USA) according to the manufacturer’s
instructions. To determine mature miRNA expression
levels, qRT-PCR was performed using a SYBR Premix Ex
Taq (TaKaRa, Japan) on a Thermal Cycler Dice Real
Time System (TaKaRa) with the following protocol: 30s
at 95 °C followed by two-step PCR for 40 cycles of 95 °C
for 5 s and 60 °C for 60s. MiRNA expression levels were
normalized against the endogenous U6 small nuclear
RNA (U6 snRNA) control. ADAM10 expression was
measured by SYBR green qPCR assay and GAPDH was
used as an endogenous control. The relative expression
level of miR-655-3p in each paired tumor and adjacent
non-tumorous tissue was calculated by the 2-ΔΔCT
method. The sequences of the PCR primers were as fol-
lows: miR-655-3p forward, 5’-CCGCGATAATACATG
GTTAACCTC-3’, and reverse primer was Uni-miR qPCR
primer (TaKaRa); U6 forward, 5’-CTCGCTTCGGCAG-
CACA-3’ and U6 reverse, 5’-AACGCTTCACGAATTT
GCGT-3’; ADAM10 forward, 5’-CTGCCCAGCATCT-
GACCCTAA-3’ and reverse, 5’-TTGCCATCAGAACTG
GCACAC-3’; GAPDH forward, 5’CTCCTCCTGTTCGA
CAGTCAGC-3’, and reverse 5’-CCCAATACGACCAAA
TCCGTT-3’.
Oligonucleotides transfection
The miR-655-3p agomiR (agomiR-655-3p), antagomiR
(anti-miR-655-3p), small interfering RNA for ADAM10
(siADAM10) and their negative control (Neg.Cont) Oli-
gonucleotides used in this study were purchased from
Shanghai GenePharma Co. Ltd. Transfection was per-
formed using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s protocol. The sequences of Oligonu-
cleotides were as follows: agomiR-655-3p, sense 5’-





-3’; negative control, 5’-UUGUACUACACAAAAGUACU
G-3’; Si-ADAM10, 5’-CAGUGUGCAUUCAAGUCAA-3’.
Luciferase assay
The wild-type ADAM10-3’UTR(WT) and mutant ADA
M10-3’UTR(MUT) containing the putative binding site of
miR-655-3p were established and cloned in the Firefly
luciferase expressing vector pMIR-REPORT (Obio
Technology, China). Liver cancer cells were seeded into
24-well plates the day before transfection, and trans-
fected with either the pMIR-REPORT-ADAM10-3’
UTR-WT or the pMIR-REPORT-ADAM10-3’ UTR-
MUT reporter vector, together with the Renilla
luciferase-expressing vector pRL-TK (Promega) and
agomiR-655-3p or miR-Neg.Cont using Lipofectamine
2000 (Invitrogen). After 48 h, cells were harvested, and
firefly and Renilla luciferase activities were measured
using the dual-luciferase reporter assay system (Pro-
mega, Madison, WI).
Cell migration and invasion assays
After 48 h of transfection, cell concentration in each
group was adjusted to 2 × 105 cells/mL with serum-free
medium. The upper chamber of Transwell chamber (Co-
star; 24-well insert, pore size: 8 μm) was filled with
200 μl cell suspension, and the lower chamber was filled
with 500 μL of medium supplementing 15 % FBS. For
the invasion assay, polycarbonate filters coated with
50 μL Matrigel (1:9, BD Bioscience) were placed in a
Transwell chamber. Three wells were used for each
group. Cells were incubated for 24 h for the migration
assay and 48 h for the invasion assay. Then, the cells on
the upper surface were wiped slightly using cotton
swabs, and the cells on the lower surface were fixed with
4 % paraformaldehyde and stained with 0.1 % crystal vio-
let. The migratory cells were visualized and counted in
five random visual fields per insert under an inverted
microscope at 200× magnification (Nikon Microphot-
FX, Japan).
MTT assay
After transfection, 5000 cells/well were seeded in 96-
well plates in media containing 10 % FBS and incubated
for 0, 24 h, 48 h, 72 h. On the indicated days, 3-(4,5)-
dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide
(MTT) (KyeGEN BioTECH, Nanjing, China) was added
into each well according to the manufacturer’s instruc-
tions, and the cells were incubated for 4 h at 37 °C. The
supernatants were then removed and 150uL of DMSO
(Sigma-Aldrich, Germany) was added to per well to dis-
solve the formazan crystals. Absorbance levels were
measured at the wavelength of 490 nm using an auto-
matic microplate reader (Gene, HK). The data derived
from triplicate samples are presented as mean ± s.d.
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Colony formation assay
After transfection, 500 cells per well were counted and
seeded in 6-well plates. The plates were incubated for
10 days, then the cells were fixed by 4 % paraformalde-
hyde and stained using 0.1 % crystal violet. Colonies
were counted only if they included 50 cells at least. Trip-
licate independent experiments were performed and all
the visible colonies were calculated manually.
Western blot
Cell samples were washed with ice-cold PBS and then
lysed by RIPA (Beyotime, China) containing protease
inhibitors (Beyotime, China). Cell protein lysates were
separated in 10 % SDS-PAGE and then transferred onto
a polyvinylidene difluoride (PVDF) membrane (Milli-
pore, USA). The membranes were blocked by 5 % skim
milk soluted in TBST buffers, and were incubated with
primary antibodies for ADAM10, c-myc (Abcam, UK),
E-cadherin, MMP9 (Santa Cruz Biotechnology, USA),
β-catenin and cyclinD1 (ProteinTech Group, USA)
overnight at 4 °C. PVDF membranes were washed in
TBST and incubated with horseradish peroxidase-
conjugated secondary antibodies (ProteinTech Group,
USA). Antibody against GAPDH (Cell Signaling Tech-
nology, USA) was used as an internal control. Antibody
against Histone H3 (Abcam, UK) was used as an in-
ternal control for nuclear β-catenin. The protein of
interest was visualized using ECL Western blotting sub-
strate (Pierce, USA).
Immunohistochemical (IHC)
Formalin-stabilised liver tissue specimens were embed-
ded in paraffin and cut into 4 μm sections for use in
immunohistochemistry. After general deparaffinization,
antigen retrieval was carried out for 30 sec with an
autoclave using 0.01 mol/l sodium citrate buffer,
pH 6.0. H2O2 (0.3 %) was used to block endogenous
peroxidase activity for 30 min at 37 °C, and non-
specific immunoglobulin binding sites were blocked by
normal goat serum for 30 min at 37 °C. Sections were
then incubated overnight with primary antibody(A-
DAM10,1:300, Abcam) at 4 °C, rinsed with PBS, and in-
cubated with the appropriate secondary antibody for
30 min. The peroxidase reaction was developed with 3,
3-diaminobenzidine tetrahydrochloride (DAB).Sections
were counterstained with Mayer’s hematoxylin, dehy-
drated, cleared in xylene, and mounted in Permount.
Statistical analysis
The statistical analyses were performed using the SPSS
17.0 software. Parametric data were presented as mean ±
SEM, and differences between each group were analyzed
using the Student’s t-test. The association between miR-
655-3p relative expression and the clinicopathological
parameters was evaluated by the χ2 test or Fisher’s exact
test when appropriate. All of the p-values reported were
two-sided, and significance was defined as p < 0.05.
Result Analysis
MiR-655-3p expression in HCC tissues and cell lines
To analysis the miRNA-655-3p expression pattern, 84
pairs of HCC tissues and adjacent non-tumorous liver
tissues were detected by qRT-PCR. The result showed
that down-regulation of miR-655-3p was observed in 61
(72.6 %) cases of HCC tissues, which was significantly
lower than that in matched non-tumorous tissues (P
<0.001, Fig. 1a, b). In cell level, miR-655-3p expression
was lower in the HCCLM3, HepG2, SK-hep1, MHCC-
97H, Huh7, MHCC-97 L cell lines than that in the nor-
mal liver cell line LO2 (Fig. 1c). All the above results
indicated that miR-655-3p was down-regulated in HCC.
Association of miR-655-3p expression with
clinicopathological features
In order to explore the potential clinical significance of
miR-655-3p in HCC patients, the cases were divided into
miR-655-3p low-expression group (n = 51) and mid/
high-expression group (n = 33), according to the relative
ratio of miR-655-3p expression in tumor/adjacent non-
tumor < or > 0.5. The correlation between miR-655-3p
expression and clinicopathological characteristics was
shown in Table 1. MiR-655-3p expression was positively
associated with tumor size (p = 0.035), PVTT (p = 0.028),
TNM stage (p = 0.004) and metastasis (p = 0.001), re-
spectively. However, it was no correlations with gender,
age, preoperative serum AFP and histological differenti-
ation. Based on these findings, we speculated miR-655-
3p might play a vital role in HCC development.
Ectopic expression of miR-655-3p inhibits HCC cell lines
proliferation
To examine the functional roles of miR-655-3p in HCC,
we upregulated HCCLM3 and HepG2 cells by miR-655-
3p agomiR (100nM) transfection. Overexpression of
miR-655-3p in the two HCC cell lines were confirmed
by qRT-PCR after transfection for 48 h (Fig. 2a, b). Then
MTT and colony formation assays were performed to
detected proliferation ability. Compared to the negative
control group, the cancer cell proliferation was dramat-
ically inhibited in miR-655-3p overexpression group by
MTT analysis after transfection for 48 h and 72 h
(Fig. 2d, e). Consistent with the MTT assay, colony for-
mation assay also showed that miR-655-3p overexpres-
sion led to a significant reduction of colony number in
HCC cells (Fig. 2g, h). Conversely, miR-655-3p inhibitor
significantly promoted the proliferation potential in
Huh7 cells both in MTT and colony formation assays
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(Fig. 2c, f, i). These results proved that miR-655-3p in-
hibit proliferation in HCC.
Restoration of miR-655-3p represses migration and
invasion of HCC cells
To investigate the function of miR-655-3p in cell migra-
tion and invasion, transwell chamber assay was per-
formed in HCC cells. We found enhancement of the
expression of miR-655-3p in HepG2 and HCCLM3 cells
could significantly inhibit cell invasion and migration
abilities. The number of invasive and migrated cells in
the miR-655-3p overexpression group(82 ± 5 and 58 ± 6,
respectively) was significantly decreased, compared with
the negative control group (180 ± 8 and 105 ± 7, respect-
ively) in HepG2 cells. The same results were also ob-
served in HCCLM3 cells (97 ± 8 and 87 ± 8 vs. 212 ± 24
and 116 ± 10, respectively). Conversely, anti-agomiR-
655-3p significantly increased the cell migration and in-
vasion of the Huh7 cells (202 ± 10 and 182 ± 8 vs. 92 ± 6
and 79 ± 6) (Fig. 3). Based on these results, we con-
cluded that miR-655-3p decreased the migration and
invasion of HCC cells.
MiR-655-3p can upregulate E-cadherin expression and
inhibit β-catenin signal pathway in HCC cells
To better understand the underlying molecular mechan-
ism of miR-655-3p inhibiting proliferation and metasta-
sis of HCC, we detected the expression of potential
proliferation and metastasis-associated proteins by
western blot. The results showed that miR-655-3p up-
regulation in HCCLM3 and HepG2 cells increased E-
cadherin and decreased the nucleus β-catenin (the
total β-catenin showed no change), cyclinD1, c-myc
protein levels(Fig. 4a, b, c). Conversely, inhibiting miR-
655-3p in Huh7 cells decreased E-cadherin and
unregulated nucleus β-catenin, cyclinD1 and c-myc
proteins (Fig. 4a, d). Only nucleus β-catenin decrease
after miR-655-3p overexpression indicated that miR-
655-3p may affect the distribution of β-catenin. All
these results suggested that miR-655-3p might influence
the biological behavior of HCC by regulating E-cadherin
expression and inhibiting β-catenin signal pathway.
ADAM10 is a direct target of miR-655-3p in HCC
It has been demonstrated miRNA relies on its regulating
target genes to achieve its biological function [17].
Therefore, we identified miR-655 target genes using the
target prediction tool, miRwalk, a comprehensive data-
base on miRNAs with six established program (miRanda,
miRDB, miRWalk, TargetScan, RNA22, and PITA) [18].
There were no miR-655-3p binding sites predicted on
mRNA of E-cadherin, β-catenin, cyclinD1 and c-myc.
While, ADAM10 was one of the gene that was predicted
to binding miR-655 by at least five program and related
to HCC biological progress according to the relevant
previous reports [19, 20].
Fig. 1 MiR-655-3p is low-expressed in HCC tissues and cell lines. a QRT-PCR analysis of miR-655-3p expression in 84 pairs HCC and their
corresponding adjacent nontumorous livers tissues. The expression of miRNA was normalized to U6 snRNA. b Relative miR-655-3p expression levels
in HCC tissues and adjacent normal regions; c QRT-PCR analysis of miR-655-3p expression in HCC cells (Bel-7402, MHCC-97 L, MHCC-97H,
HepG2, SK-Hep1, HCCLM3, Huh7) and normal hepatocytes (LO-2)
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As predicted, overexpression of miR-655-3p in HepG2
and HCCLM3 cells decreased the expression of
ADAM10 at both the mRNA and protein levels, whereas
miR-655-3p inhibitor increased its expression in Huh7
cells (Fig. 5a, b, d). Using TargetScan, we located poten-
tial binding sites for miR-655-3p at the 3’UTR of
ADAM10 mRNAs (Fig. 5c). Then, a dual-luciferase re-
porter system was carried out to determine whether
ADAM10 was a direct target of miR-655-3p. Overex-
pression of miR-655-3p significantly suppressed the lu-
ciferase activity of the wild-type ADAM10 3’-UTR, but
failed to affect the mutant 3’-UTR in HCCLM3 and
HepG2 cells (Fig. 5e, f ). Taken together, these results
demonstrated that ADAM10 was a direct target of
miR-655-3p.
Loss-of function of ADAM10 mimicked impact of
miR-655-3p on HCC cell proliferation and metastasis
To confirm whether miR-655-3p dependent repression
of HCC cell biological behaviors was mediated by
ADAM10, we investigated the expression and role of
ADAM10 in HCC. ICH results showed that expression
Fig. 2 MiR-655-3p suppressed hepatocellular carcinoma cell growth and proliferation abilities. a, b, c. QRT-PCR analysis of miR-655-3p transfection
efficiency after the miR-655-3p agomiR, or antagomiR transfection in HCC cells. d, e, f. The MTT assay analysis was used to evaluate the proliferation of
HCC cells after transfection with the miR-655-3p agomiR, antagomiR or controls. g, h, i. Colony formation assay analysis of HCC cells after treatment
with miR-655-3p agomiR or antagomiR or controls. (Data are mean ± SEM (n = 3), *p < 0.05, **p < 0.01, and ***p < 0.001 VS controls)
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of ADAM10 is strongly positively stained in HCC tis-
sues, while, absent or sporadic in non-tumorous liver tis-
sues. And ADAM10 is located in the cytoplasm and cell
membrane in HCC ADAM10-positive cells (Fig. 6a, b).
The further results revealed that si-ADAM10 mediated
downregulation of ADAM10 expression inhibited the
proliferation, migration and invasion both in HepG2
and Huh7 cells (Fig. 6d, e, f, g). The effect of ADAM10
silencing was similar to the effect of miR-655-3p over-
expression on proliferation, migration and invasion of
HepG2 cells (Fig. 2d, Fig. 3). Moreover, inhibition of
ADAM10 expression significantly attenuated the abil-
ities of cell proliferation, migration and invasion pro-
moted by anti-miR-655-3p in Huh7 cells (Fig. 6c, h).
These results demonstrated that miR-655-3p inhibited
the proliferation, migration and invasion of HCC cells
by targeting ADAM10.
Discussion
Tumor invasion, metastatic dissemination, recurrence,
and drug resistance have been identified as the major
causes of the poor clinical outcome in HCC patients
[1–4]. More and more miRNAs were converged to
account for characters of various tumor processes, in-
cluding tumor initiation, development and metastasis
[6, 21]. MiR-655-3p was encoded in 14q32 locus, a re-
gion that has been implicated in oncogenesis and metasta-
sis of diverse cancer types [12, 13]. Yang et al. showed
miR-655 expression was decreased in esophageal squa-
mous cell carcinoma (ESCC) and overexpression of miR-
Fig. 3 Effect of miR-655-3p on invasion and migration in HCC. Restoration of miR-655-3p repressed migration and invasion of HepG2 and
HCCLM3 cells; and inhibiting miR-655-3p expression promoted cell migration and invasion in Huh7 cells. Transwell analysis was used. Data are
mean ± SEM (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001 compared to controls
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655 inhibited ESCC cell invasiveness by targeting
PTTG1 [14]. Yosuke et al. reported that miR-655 re-
presses EMT progress through inducing inactivation of
the TGF-β signaling pathway by targeting ZEB1 and
TGFBR2, in ESCC [15]. Kitamura et al. demonstrated
that miR-134/487b/655 cluster regulate TGF-β induced
EMT and drug resistance to Gefitinib by targeting
MAGI2 in lung adenocarcinoma cells [16]. In addation,
Zhang et al. showed that Norcantharidin suppress glio-
blastoma cell invasion through modulation of miR-655-
mediated SUMO-specific protease 6 translation [22].
Various publications have associated the dysregulation
of miR-655 with cancer progress. However, the rela-
tionship between miR-655 and HCC remains unknown.
In this study, we first demonstrated that miR-655-3p
was significantly down-regulated in human HCC tissues
and cell lines. We also found that down-regulation of
miR-655-3p expression levels was significantly associated
with the tumor size, portal vein tumor thrombo-
sis(PVTT) status, TNM stage and metastasis status.
Using MTT, colony formation and transwell assays, we
found that overexpression of miR-655-3p could suppress
the proliferation, migration and invasion ability in HCC
cells in vitro, indicating the crucial role of miR-655-3p
in HCC development. Based on above results, miR-655-
3p might was a tumor suppressor in HCC. Then, the
underlying molecular mechanism of miR-655-3p inhibit-
ing HCC progress was detected, and the results showed
Fig. 4 MiR-655-3p up-regulated E-cadherin expression and inhibited β-catenin signal pathway in HCC cells. a Western blot analysis of E-cadherin
and β-catenin signal pathway proteins after transfection of miR-655-3p agomiR or antagomiR or controls. b, c, d Column charts were used to
display the changes of protein expression. Gray value was analyzed by Image J Software. Histone H3 was used an internal control for nuclear
β-catenin, and GAPDH for others. Data are mean ± SEM (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001 compared to controls
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upregulating miR-655-3p expression increased E-cadherin
protein but decreased the nucleus β-catenin, cyclinD1 and
c-myc expression. β-catenin is known to interact with
TCF/LEF family of transcription factors to induce gene
expression, such as cyclinD1 and c-myc [21, 23–25].
These results indicate that miR-655-3p might influence
the biological behavior of HCC by regulating E-cadherin
expression and inhibiting β-catenin signal pathway.
A disintegrin and metalloproteinase 10 (ADAM10),
has been proved to be upregulated in various cancers
and involved in cancer progression and metastasis, such
as pancreatic cancer, breast cancer, lung cancer and he-
patocellular carcinoma [26–30]. ADAM10 is reported
as a sheddase that can cleave transmembrane proteins
such as amyloid precursor protein (APP), E-cadherin,
N-cadherin, CD44 and Notch, all of which play a sig-
nificant role in proliferation, migration, invasion or
stemness of cancer cells [27, 28, 31–35]. Of particular
importance is that ADAM10 is identified as an onco-
gene contributing to HCC progression, such as metas-
tasis, invasion and drug resistance of Sorafenib [18, 19].
In our study, we also found that ADAM10 silencing
Fig. 5 ADAM10 is a direct target of miR-655-3p in HCC. a. qRT-PCR analysis of ADAM10 mRNA expression after the miR-655-3p agomiR, or
antagomiR transfection in HCC cells. b, d. Western blot analysis of ADAM10 protein expression after the miR-655-3p agomiR, or antagomiR
transfection in HCC cells; and their Column charts analysis. c. The predicted interaction site of miR-655-3p and candidate target gene ADAM10
wild-type 3’-UTR and serial deleted forms of the 3’UTR reporters. e, f. Luciferase assay of co-transfected with miR-655-3p agomiR and pMIR-
REPORT-ADAM10 plasmid (miR-NC and miR-655-3p with ADAM10 WT 3’UTR; miR-NC and miR-655-3p with ADAM10 MUT 3’UTR) after 24 h.
Data are mean ± SEM (n = 3). *p < 0.05, and **p < 0.01 compared to controls
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suppresses HCC proliferation, migration and invasion in
vitro, and using a luciferase-based reporter assay, we dem-
onstrated that miR-655-3p could bind to a sequence
within the 3’-UTR of ADAM10. MiR-655-3p-mediated
control of ADAM10 expression was further validated by
complementary gain and loss-of-function approaches.
Thus, we conclude that miR-655-3p mediates HCC pro-
gress by targeting the 3’-UTR of ADAM10. Neha et al. re-
ported that inhibiting ADAM10 expression subsequently
diminishes β-catenin intracellular signaling and repress
TCF/LEF target gene expression [27], which is similar
to our founding that miR-655-3p could reduce E-
cadherin protein level and inhibit β-catenin pathway by
target regulating ADAM10 in HCC. Besides, ADAM10
can exert different functions regulated by multiple
micrornas. For example, miR-144/451 inhibits cancer
metastasis by targeting ADAMTS5 and ADAM10 in
human epithelial cancers [36]; miR-122-5p reduces
trastuzumab resistance by regulating ADAM10 in
breast cancer [37]; miR-140-5p can repress tumor pro-
gression by targeting ADAM10 in human tongue and
hypopharyngeal squamous cancer cells [38, 39]. Our
study provided a new mechanism accounting for
ADAM10 dysregulation in HCC.
Conclusion
In conclusion, our study demonstrate that miR-655-3p
functions as tumor suppressor by directly targeting
ADAM10 and indirectly regulating β-catenin pathway in
HCC progression and metastasis. These findings provide
a new insight into the molecular pathogenesis of HCC
and identify miR-655-3p as a novel therapeutic candi-
date target for HCC.
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